Merck CEO Rob Davis

Mer­ck emerges as lead bid­der in po­ten­tial Ac­celeron buy­out with deal pos­si­ble this week — re­port

With ru­mors swirling about a po­ten­tial buy­out of biotech Ac­celeron and its lead PAH drug so­tater­cept, mar­ket watch­ers have been keep­ing close tabs on in­dus­try movers and shak­ers due up for an ex­pen­sive bolt-on. Ac­cord­ing to a new re­port, it ap­pears Mer­ck may be the one.

Mer­ck is in “ad­vanced talks” on a deal to ac­quire Cam­bridge, MA-based Ac­celeron in what pre­vi­ous re­ports pegged as a po­ten­tial $11 bil­lion buy­out, the Wall Street Jour­nal re­port­ed Mon­day. A deal could come as ear­ly as this week, ac­cord­ing to the Jour­nal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.